Delcath Systems Inc. has announced the publication of a retrospective clinical study evaluating the use of its CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) in patients with liver-dominant metastatic uveal melanoma. The study, conducted at Asklepios Hospital Barmbek in Hamburg, Germany, and published in the journal Cancers, analyzed outcomes from 38 patients who underwent 99 PHP procedures between April 2014 and March 2024. Results demonstrated a median overall survival of 29.1 months from the first PHP treatment, with improved survival observed in patients receiving three or more treatment cycles. The study reported no treatment-related deaths and procedure-related adverse events of grade 2 or higher in 10.5% of patients. These findings reflect data from real-world clinical practice and suggest that institutional experience and patient selection may influence outcomes. The results have already been published and are available in the journal Cancers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203718788) on December 03, 2025, and is solely responsible for the information contained therein.
Comments